Evolus, Inc. SEC filings EOLS
Evolus, Inc. has 557 filings in SEC EDGAR's recent list, going back to Feb 27, 2013. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 12, 2026 | — |
| CORRESP | Letter to the SEC | Jun 10, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2026 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2024 | — |
| CORRESP | Letter to the SEC | Dec 12, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2024 | — |
| EFFECT | Filing | Jun 8, 2023 | — |
| CORRESP | Letter to the SEC | Jun 7, 2023 | — |
| CORRESP | Letter to the SEC | Apr 14, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2023 | — |
| D | Filing | Jul 17, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2019 | — |
| CORRESP | Letter to the SEC | Aug 12, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2019 | — |
| EFFECT | Filing | Apr 15, 2019 | — |
| CORRESP | Letter to the SEC | Apr 11, 2019 | — |
| CORRESP | Letter to the SEC | Apr 10, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2019 | — |
| EFFECT | Filing | Jul 18, 2018 | — |
| CORRESP | Letter to the SEC | Jul 16, 2018 | — |
| CORRESP | Letter to the SEC | Jul 16, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2018 | — |
| DRS | Filing | Jul 2, 2018 | — |
| CT ORDER | Filing | Feb 8, 2018 | — |
| EFFECT | Filing | Feb 7, 2018 | — |
| CERT | Filing | Feb 5, 2018 | — |
| CORRESP | Letter to the SEC | Feb 5, 2018 | — |
| CORRESP | Letter to the SEC | Feb 5, 2018 | — |
| 8-A12B | Filing | Feb 1, 2018 | — |
| CORRESP | Letter to the SEC | Feb 1, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2018 | — |
| CORRESP | Letter to the SEC | Jan 25, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2018 | — |
| CORRESP | Letter to the SEC | Jan 8, 2018 | — |
| DRSLTR | Filing | Dec 20, 2017 | — |
| DRS/A | Filing | Dec 20, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2017 | — |
| DRS/A | Filing | Nov 21, 2017 | — |
| DRSLTR | Filing | Nov 21, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2017 | — |
| DRS | Filing | Aug 28, 2017 | — |
| D | Filing | Feb 27, 2013 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newport Beach, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1570562
- Former names
- Evolus, Inc. (until Nov 4, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.